Objectives
T2DM, Infection, Cancer
INSULIN RESISTANCE, TYPE 2 DIABETES MELLITUS, INFECTION, CANCER
Edited by: Qinglong Wu, Baylor College of Medicine, United StatesReviewed by: Bo Zhu, University of Texas MD Anderson Cancer Center, United States; Ravi Verma, Department of Pathology and Immunology, Baylor College of Medicine, United States†These authors have contributed equally to this work‡ORCID: Yongsong Chen, This article was submitted to Intestinal Microbiome, a section of the journal Frontiers in Cellular and Infection MicrobiologyRecent studies have shown that fecal microbiota transplantation (FMT) improved the metabolic profiles of patients with type 2 diabetes mellitus (T2DM), yet the effectiveness in reversing insulin resistance and increasing metformin sensitivity in T2DM patients have not been reported. In this study, we evaluated the improvements of T2DM patients and their gut microbiota by FMT alone and FMT plus metformin.